Thư viện công bố kiểm nghiệm lâm sàng

Danh sách các công bố nghiên cứu lâm sàng về hiệu quả của Bào tử lợi khuẩn LiveSpo

2025

LiveSpo® NAVAX – Nature.com
Nasal-spraying Bacillus spore probiotics for pneumonia in children with respiratory syncytial virus and bacterial co-infections: a randomized clinical trial
https://www.nature.com/articles/s43856-025-01029-9

LiveSpo® DIA30 – Nature.com
High-dose multi-strain Bacillus probiotics enhance treatment and reduce antibiotic usage in children with persistent diarrhea through immune and microbiota modulation
https://www.nature.com/articles/s41598-025-15199-y

LiveSpo® NAVAX’s report on Nature.com 2025
Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial
https://www.nature.com/articles/s41598-025-87372-2

2024

LiveSpo® CLAUSY’s report on Nature.com 2024​
Promising clinical and immunological efficacy of Bacillus clausii spore probiotics for supportive treatment of persistent diarrhea in children
https://www.nature.com/articles/s41598-024-56627-9

LiveSpo® PREG-MOM & LiveSpo® KIDS on Clinicaltrials.gov, NIH US, 2024​
Effectiveness of Bacillus spore probiotics in reducing constipation, anorexia, and slow weight gain in children
https://classic.clinicaltrials.gov/ct2/show/NCT06154525

LiveSpo® NAVAX on Clinicaltrials.gov, NIH US, 2024​
Efficacy of probiotics (LiveSpo® NAVAX) in preventing respiratory diseases in children
https://classic.clinicaltrials.gov/ct2/show/NCT06148194

LiveSpo® DIA30 on the ClinicalTrials.gov - U.S. National Library of Medicine​
Effects of Probiotic in Treatment of Persistent Diarrhea in Children
https://clinicaltrials.gov/ct2/show/NCT05812820

LiveSpo® X-Secret on Clinicaltrials.gov, NIH US, 2024​
Effects of LiveSpo® X-SECRET in supportive treatment of vaginitis
https://classic.clinicaltrials.gov/ct2/show/NCT06165354

2023

LiveSpo® NAVAX’s report on Nature.com 2023​
Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal spraying Bacillus spore probiotics
https://www.nature.com/articles/s41598-023-41763-5

LiveSpo® NAVAX on Clinicaltrials.gov, NIH US, 2023​
LiveSpo® NAVAX supports the treatment of acute rhinosinusitis and otitis media
https://clinicaltrials.gov/ct2/show/NCT05804123

LiveSpo® NAVAX on Clinicaltrials.gov, NIH US, 2023​
Efficacy of LiveSpo® NAVAX in supportive treatment of pneumonia in children with RSV and bacterial co-infections
https://classic.clinicaltrials.gov/ct2/show/NCT05929599

2022

LiveSpo® NAVAX’s report on Nature.com 2022​
Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection
https://www.nature.com/articles/s41598-022-16136-z

American Society for Microbiology (ASM), Washington DC 2022
Randomized controlled trial of nasal-spraying Bacillus spores in symptomatic treatment for children with acute RSV infection
https://www.abstractsonline.com/pp8/#!/10522/presentation/5206

American Society for Microbiology (ASM), Washington DC 2022
Effective symptomatic treatment for children infected with Influenza virus by nasal-spraying Bacillus spore suspension
https://www.abstractsonline.com/pp8/#!/10522/presentation/2271 ​​​​​​​

LiveSpo® NAVAX on Clinicaltrials.gov, NIH US, 2022​
Effects of Nasal-spraying LiveSpo® NAVAX in Treatment of Acute Respiratory Infections in Children
https://clinicaltrials.gov/ct2/show/NCT05164692 ​​​​​​​

LiveSpo® NAVAX – ClinicalTrials.gov (NIH, US)
Effects of nasal-spraying LiveSpo® NAVAX in treatment of Influenza virus in children
https://clinicaltrials.gov/ct2/show/NCT05378022

2020

FDA NDI 1167 for LiveSpo® COLON
Bacillus clausii and Bacillus subtilis, under tradename LiveSpo® COLON – Ana Bio Research & Development JSC. Letter from FDA CFSAN to Ana Bio R&D JSC (10/15/2020)
https://www.fda.gov/media/160660/download